SpeechVive Completes Funding to Move Speech Aid for Parkinson's Patients to the Public

LAFAYETTE, Ind. & FORT WAYNE, Ind.--()--SpeechVive Inc. announces the completion of nearly $700,000 in funding to move a speech aid innovation for people with Parkinson's disease to the public.

Ambassador Enterprises, an Indiana-based for-profit philanthropic equity investment firm, is providing Series A funding to support the U.S. sales launch of the SpeechVive device. The technology is a behind-the-ear smart device that helps people with Parkinson's disease speak more loudly and communicate more effectively.

"Based on the market research we have conducted and the queries we have received from health care professionals and individuals, there is a strong need for a product like SpeechVive," said Steve Mogensen, president and CEO of SpeechVive. "Our plan is to launch the sales of SpeechVive in the U.S. during the second quarter of this year."

The technology was developed over the past decade by Jessica Huber, associate professor in Purdue University's Department of Speech, Language and Hearing Sciences. The focus of Huber's research is the development and testing of behavioral treatments to improve communication and quality of life in older adults and people with degenerative motor diseases.

SpeechVive reduces the speech impairments associated with Parkinson's disease, which causes people with the disease to speak in a hushed, whispery voice, have mumbled speech and commonly impacts their ability to communicate effectively.

"The clinical data we have collected over the past four years demonstrates that SpeechVive is effective in 90 percent of the people using the device," Huber said.

More than 1.5 million people in the U.S. are diagnosed with Parkinson's disease, and it is one of the most common degenerative neurological diseases. About 89 percent of those with Parkinson's disease have voice-related change, or affecting how loudly they speak, and about at least 45 percent have speech-related change, or affecting how clearly they speak.

"Ambassador Enterprises is deeply committed to developing healthy lives, healthy communities and healthy futures," said Brad Miller of Ambassador Enterprises. "Since SpeechVive is a technology that can improve the overall quality of life for people, it is exactly the type of innovation we wish to invest in and support."

Huber previously had received $2.25 million in research funding for SpeechVive from the National Institutes of Health (NIH).

Contacts

Purdue Research Foundation
Cynthia Sequin, 765-588-3340
casequin@prf.org

Release Summary

SpeechVive Inc. will launch U.S. sales of a device that reduces speech impairments associated with Parkinson's disease. It received nearly $700,000 in funding from Indiana-based Ambassador Ventures.

Sharing

Contacts

Purdue Research Foundation
Cynthia Sequin, 765-588-3340
casequin@prf.org